Paris, June 3, 2024
BIOPHTA, a preclinical biotech company developing a game-changing technology for the treatment of eye diseases, has just closed a € 6.5 million Seed round to bring its patented technology to clinical development.
This funding round was led by leading European VCs – UI Investissement (via the Pertinence Invest 2 Fund, advised by Mérieux Equity Partners), Elaia and GO Capital – as well as one major ophthalmology player, Unither Pharmaceuticals and HTL Biotechnology, the global leader in production and development of pharma grade biopolymers.
如需了解我们的最新消息,
![](https://htlbiotech.com/wp-content/uploads/2023/08/partner-1.jpg)
阅读
更多文章
-
文章 21 6 月, 2024
HTL生物科技(海雅透凝)亮相2024年CPHI中国展
CPHI中国展是亚洲领先的制药行业交易与交流盛会,汇聚了3,500多家参展商和来自制药行业的90,000多名专业人士。
-
文章 13 6 月, 2024
探索我们的质量政策
在HTL生物科技(海雅透凝),我们坚信携手并进,超越自我,以达到最高的质量标准。
-
新闻稿 6 5 月, 2024
收购Modern Meadow用于美容和生物医学应用的人类重组胶原蛋白平台
TL生物科技(海雅透凝) 通过收购美国公司Modern Meadow(位于新泽西州纳特利)的美容和生物医学部门,巩固了其在制药级生物聚合物生产和开发领域的全球领先地位。值得注意的是,此次收购包括Modern Meadow的重组蛋白平台,其中最先进的产品是人类重组胶原蛋白III型(rhCOL3)。